Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 13, 1411 - 1413 (2007)
doi:10.1038/nm1207-1411
Building the bionic T cell
Drew M Pardoll1
- Drew M. Pardoll is Abeloff Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA. e-mail: dmpardol@jhmi.edu
Abstract
Adoptive T cell transfer studies in mice and in cancer patients have shown substantial potential, but also major barriers, for successful therapeutic outcomes. A new strategy may overcome some of these barriers. T cells can now be engineered with 'autocostimulation' properties along with chimeric receptors specific for tumor antigens (pages 1440–1449).
Ever since adoptive T cell transfer studies in mice and then in humans with cancer showed the capacity of tumor-specific T cells to treat established cancers1, 2, 3, 4, tumor immunologists have been trying to do to T cells what was done to Steve Austin and Jaime Sommers in The Six Million Dollar Man—namely, engineer them to be better, stronger, faster. For T cells, that engineering is done via gene transfer.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Tumor reactive T cells get a boostNature Biotechnology Research News (01 Dec 2002)
Cancer T cell therapy expandsNature Medicine News and Views (01 Mar 2003)
RESEARCH
T cell?encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejectionNature Medicine Article (01 Dec 2007)
T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120Gene Therapy Research Article
See all 5 matches for Research